-
Doxorubicin
- indication:For the treatment of Koposi's sarcome connected to AIDS.
- pharmacologypharmacology:
- mechanism: Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
- toxicity: LD<sub>50</sub>=21800 ug/kg (rat, subcutaneous)
- absorprion:
- halflife: 55 hours
- roouteelimination: Plasma clearance is in the range 324 to 809 mL/min/m2 and is predominately by metabolism and biliary excretion.
- volumedistribution:
- clearance: * 324-809 mL/min/m2 * 1088 mL/min/m2 [Men] * 433 mL/min/m2 [Women] * 1540 mL/min/m2 [children greater than 2 years of age receiving administration of 10 to 75 mg/m2 doses] * 813 mL/min/m2 [infants younger than 2 years of age receiving administration of 10 to 75 mg/m2 doses]